Nonalcoholic steatohepatitis: pathologic features and differential diagnosis

Seminars in Diagnostic Pathology

Volumn 22, Issue 4, 2005, Pages 330-338

  Brunt, Elizabeth M ^a  

^a Saint Louis University   (United States)

Author keywords

Fatty liver disease; Nonalcoholic; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; PIOGLITAZONE; ROSIGLITAZONE; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; GASTRIC BANDING; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LAPAROSCOPIC SURGERY; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; MALLORY BODY; MICROSCOPY; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCORING SYSTEM;

ADOLESCENT; ADULT; BIOPSY; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; MALE;

EID: 33746383056     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2006.04.002     Document Type: Article

References (94)

1. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980) 434-438
2. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease. a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
3. Haque M., and Sanyal A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 16 (2002) 709-731
4. Sanyal A.J. Insulin resistance and nonalcoholic steatohepatitis. fat or fiction?. Am J Gastroenterol 96 (2001) 274-276
5. Diehl A.M., Li Z.P., Lin H.Z., et al. Cytokines and the pathogenesis of nonalcoholic steatohepatitis. Gut 54 (2005) 303-306
6. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue: emerging role in nonalcoholic fatty liver disease. Nat Clin Pract 2 (2005) 273-280
7. Hui J.M., Hodge A., Farrell G.C., et al. Beyond insulin resistance in NASH. TNF-a or adiponectin?. Hepatology 40 (2004) 46-54
8. Musso G., Gambino R., Durazzo M., et al. Adipokines in NASH. postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42 (2005) 1175-1183
9. Browning J.D., Kumar K.S., Saboorian H., et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99 (2004) 292-298
10. Weston S.R., Leyden W., Murphy R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41 (2005) 372-379
11. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance. a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
12. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 118 (2000) 1117-1123
13. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
14. Ong J.P., Elariny H., Collantes R., et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15 (2005) 310-315
15. Dixon J.B., Bhatal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease. predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001) 91-100
16. Shimada M., Hashimoto E., Kaneda H., et al. Nonalcoholic steatohepatitis. risk factors for liver fibrosis. Hepatol Res 24 (2002) 429-438
17. Abdelmalek M., Ludwig J., and Lindor K.D. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 20 (1995) 127-130
18. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis. clinical characterization and risk factors for underlying disease. Hepatology 29 (1999) 664-669
19. Charlton M., Kasparova P., Weston S., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplant 7 (2001) 608-614
20. Carson K., Washington M.K., Treem W.R., et al. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transplant Surg 3 (1997) 174-176
21. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplant 7 (2001) 363-373
22. Davila J.A., Morgan R.O., Shaib Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States. a population based case control study. Gut 54 (2005) 533-539
23. Dellon E.S., and Shaheen N.J. Diabetes and hepatocellular carcinoma. associations, biologic plausibility and clinical implications. Gastroenterology 129 (2005) 1132-1134
24. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis. a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990) 74-80
25. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of non-alcoholic steatohepatitis. from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
26. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
27. Shimada M., Hashimoto E., Taniai M., et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37 (2002) 154-160
28. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36 (2002) 1349-1354
29. Bencheqroun R., Duvoux C., Luciani A., et al. Hepatocellular carcinoma without cirrhosis in a patient with non-alcoholic steatohepatitis. Gastroenterol Clin Biol 28 (2004) 497-499
30. Gonzalez L., Blanc J.F., Sa Cunha A., et al. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin Liver Dis 24 (2004) 415-419
31. Bullock R.E., Zaitoun A.M., Aithal G.R., et al. Association of nonalcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. Letter to the Editor. J Hepatol 41 (2004) 685-686
32. Brunt E.M., Wolverson M.K., and Di Bisceglie A.M. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis. a case report. Semin Liver Dis 25 (2005) 230-236
33. Connor C.L. Fatty infiltration of liver and development of cirrhosis in diabetes and chronic alcoholism. Am J Pathol 14 (1938) 347-363
34. Thaler H. Relation of steatosis to cirrhosis. Clin Gastroenterol 4 (1975) 273-280
35. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease. a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
36. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improvement in nonoalcholic steatohepatitis following 48 weeks of treatment with the PPAR-g ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
37. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment fo nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
38. Brunt E.M., Neuschwander-Tetri B.A., Oliver D.A., et al. Nonalcoholic steatohepatitis. histologic features and clinical correlations with 30 blinded biopsies. Hum Pathol 35 (2004) 1070-1082
39. Brunt E.M. Alcoholic and nonalcoholic steatohepatitis. Clinics in Liver Disease 6 (2002) 399-420
40. Ruhl C.E., and Everhart J.E. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 3 (2005) 1260-1268
41. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease. Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001) 91-100
42. Adams L.A., and Angulo P. The bulge, booze and the liver. Clin Gastroenterol Hepatol 3 (2005) 1195-1197
43. Dixon J.B., O'Brien P.E., and Bhatal P.S. A wider view on diagnostic criteria of nonalcoholic steatohepatitis. (Reply). Gastroenterology 122 (2002) 841-842
44. Marchesini G., and Forlani G. NASH. From liver diseases to metabolic disorders and back to clinical hepatology. (Editorial). Hepatology 35 (2002) 497-499
45. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis. summary of an AASLD single topic conference. Hepatology 37 (2003) 1202-1219
46. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
47. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease. the Dionysos nutrition and liver study. Hepatology 42 (2005) 44-52
48. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
49. Saadeh S., Younossi Z.M., Remer E.M., et al. The utililty of radiological imaging in nonalcoholic fatty liver disease. Gastroenterolgy 123 (2002) 745-750
50. Hepburn M.J., Vos J.A., Fillman E.P., et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infectd with hepatitis C in a clinical setting. a retrospective observational study. BMC Gastroenterol 5 (2005) 1-8
51. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis. an expanded clinical entity. Gastroenterology 107 (1994) 1103-1109
52. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
53. Sorrentino P., Tarantino G., Conca P., et al. Silent non-alcoholic fatty liver disease. a clinical-histological study. J Hepatol 41 (2004) 751-757
54. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States. impact of ethnicity. Hepatology 40 (2004) 1387-1395
55. Skelly M.M., James P.D., and Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35 (2001) 195-199
56. Goldstein N.S., Hastah F., Galan M.V., et al. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol 123 (2005) 382-387
57. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
58. Day C.P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 663-678
59. Burt A.D., Mutton A., and Day C.P. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Liver Dis 15 (1998) 246-258
60. Itoh S., Yougel T., and Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 82 (1987) 650-654
61. Brunt E.M. Nonalcoholic steatohepatitis. Semin Liver Dis 24 (2004) 3-20
62. Brunt E.M. Nonalcoholic steatohepatitis. definition and pathology. Semin Liver Dis 21 (2001) 3-16
63. Brunt E.M., and Tiniakos D.G. Pathological features of NASH. Front Biosci 10 (2005) 1475-1484
64. Brunt E.M., and Tiniakos D.G. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 691-707
65. Brunt E.M. Pathology of hepatic iron overload. Semin Liver Dis 25 (2005) 392-401
66. Washington K., Wright K., Shyr Y., et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 31 (2000) 822-828
67. Goodman Z.D., and Ishak K.G. Occlusive venous lesions in alcoholic liver disease. Gastroenterology 83 (1982) 786-796
68. Burt A.D., and MacSween R.N.M. Hepatic vein lesions in alcoholic liver disease. retrospective biopsy and necropsy study. J Clin Pathol 39 (1986) 63-67
69. Harrison S.A., Brunt E.M., Goodman Z.D., et al. Diabetic hepatosclerosis. diabetic microangiopathy of the liver. Arch Pathol Lab Med 130 (2006) 27-32
70. Brunt E.M. Grading and staging the histopathologcial lesions of chronic hepatitis. the Knodell histology activity index and beyond. Hepatology 31 (2000) 241-246
71. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis. a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
72. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
73. Brunt E.M., Ramrakhiani S., Cordes B.G., et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 16 (2003) 49-56
74. Clouston A.D., and Powell E.E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 16 (2002) 767-781
75. Ong J.P., Younossi Z.M., Speer C., et al. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 21 (2001) 266-271
76. Sanyal A.J., Contos M.J., Sterling R.K., et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98 (2003) 2064-2071
77. Powell E.E., Jonsson J.R., and Clouston A.D. Steatosis. co-factor in other liver diseases. Hepatology 42 (2005) 5-13
78. Lonardo A., Adinolfi L.E., Loria P., et al. Steatosis and hepatitis C virus. mechanisms and significance for hepatic and extrahepatic disease. Gastroenterolgy 126 (2004) 586-597
79. Rubbia-Brandt L., Leandro G., Spahr L., et al. Liver steatosis in chronic hepatitis C. a morphological sign suggesting infection with HCV genotype 3. Histopathology 39 (2001) 119-124
80. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection fibrosis progression. Gastroenterolgy 125 (2003) 1695-1704
81. Schwimmer J.B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42 (2005) 641-649
82. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Interim results of a pilot study demonstrating the early effects of the PPAR-g ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38 (2003) 434-440
83. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis. results of a randomized trial. Hepatology 39 (2004) 770-778
84. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
85. Dixon J.B., Bhatal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease. Improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
86. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis. a pilot study. Am J Gastroenterol 100 (2005) 1072-1081
87. Lutchman G., Promrat K., Kleiner D.E., et al. Worsening of liver histology of nonalcoholic steatohepatitis (NASH) after stopping pioglitazone. Is long-term therapy needed?. Gastroenterology 128 suppl 2 (2005) 695A
88. Ghany M.G., and Doo E. Assessment of liver fibrosis. palpate, poke or pulse?. Hepatology 42 (2005) 759-761
89. Thuluvath P.J., and Krok K.L. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease. are they ready for prime time?. Am J Gastroenterol 100 (2005) 1981-1983
90. Laine F., Bendavid C., Moirand R., et al. Prediction of liver fibrosis in patients with features of metabolic syndrome regardless of alcohol consumption. Hepatology 39 (2004) 1639-1646
91. Day C.P. Who gets alcoholic liver disease. nature or nurture?. J R Coll Physicians Lond 34 (2000) 557-562
92. Hayashi P.H., Harrison S.A., Torgerson S., et al. Cognitive lifetime drinking history in nonalcoholic fatty liver disease. some cases may be alcohol related. Am J Gastroenterol 99 (2004) 76-81
93. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis 22 (2002) 185-194
94. Lewis J.H., Ranard R.C., Caruso A., et al. Amiodarone hepatotoxicity. Prevalence and clinicopathologic correlations among 104 patients. Hepatology 9 (1989) 679-685